Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

Douglas J. Schwartzentruber, M.D., David H. Lawson, M.D., Jon M. Richards, M.D., Ph.D., Robert M. Conry, M.D., Donald M. Miller, M.D., Ph.D., Jonathan Treisman, M.D., Fawaz Gailani, M.D., Lee Riley, M.D., Ph.D., Kevin Conlon, M.D., Barbara Pockaj, M.D., Kari L. Kendra, M.D., Ph.D., Richard L. White, M.D., Rene Gonzalez, M.D., Timothy M. Kuzel, M.D., Brendan Curti, M.D., Phillip D. Leming, M.D., Eric D. Whitman, M.D., Jai Balkissoon, M.D., Douglas S. Reintgen, M.D., Howard Kaufman, M.D., Francesco M. Marincola, M.D., Maria J. Merino, M.D., Steven A. Rosenberg, M.D., Ph.D., Peter Choyke, M.D., Don Vena, B.S., and Patrick Hwu, M.D.

[1]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[2]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[3]  R. Blasberg,et al.  Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts , 2010, The Journal of experimental medicine.

[4]  N. Zeps,et al.  Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Sharma,et al.  CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients , 2008, Proceedings of the National Academy of Sciences.

[6]  S. Steinberg,et al.  Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines , 2008, Clinical Cancer Research.

[7]  B. LaFleur,et al.  Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Hwu,et al.  Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy , 2007, Clinical Cancer Research.

[9]  J. Allison,et al.  Checkpoint blockade in cancer immunotherapy. , 2007, Advances in immunology.

[10]  S. Rosenberg,et al.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Bissonette,et al.  Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. Restifo,et al.  The future of interleukin-2: enhancing therapeutic anticancer vaccines. , 2000, The cancer journal from Scientific American.

[13]  F. Marincola,et al.  Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. , 1999, Journal of immunology.

[14]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.